Evidence map›Paper›PMID 31388911›Full record

ReviewJournal of general internal medicine2019

An Elusive Case of Mycosis Fungoides: Case Report and Review of the Literature.

Vincent A Pallazola, Gerard Deib, Soni Abha, Rabih M Geha, Kimiyoshi Kobayashi

Open access · bronzeAbstract readCase ReportsReview
In one paragraph

Review in Journal of general internal medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 88% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Hypopigmented Mycosis Fungoides in an 11-Year-Old Palestinian Boy.Case reports in dermatological medicine · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Vincent A PallazolaDepartment of Medicine, Johns Hopkins University School of Medicine, 600 N. Wolfe Street, Baltimore, MD, 21287, USA. vpallaz1@jhmi.edu.
Gerard DeibDepartment of Radiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Soni AbhaDepartment of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Rabih M GehaDepartment of Medicine, University of California San Francisco, San Francisco, CA, USA.
Kimiyoshi KobayashiDepartment of Medicine, Johns Hopkins University School of Medicine, 600 N. Wolfe Street, Baltimore, MD, 21287, USA.
Johns Hopkins University · USSan Francisco VA Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Erythroderma refers to a spectrum of skin diseases resulting in diffuse erythema and scaling encompassing ≥ 90% of the body surface area. The differential diagnosis ranges from primary dermatologic diseases such as atopic dermatitis and psoriasis to potentially deadly causes such as staphylococcal toxic shock syndrome, toxic epidermal necrolysis, and malignancy. Cutaneous T cell lymphoma (CTCL) is an uncommon but highly morbid cause of erythroderma. This non-Hodgkin lymphoma remains a diagnostic challenge due to its variable clinical presentation and varied histologic features. Mycosis fungoides (MF) is the most common form of CTCL. Making a timely diagnosis is challenging as it may mimic inflammatory diseases of the skin including eczema, psoriasis, lichen planus, and cutaneous lupus. We present a case of a 58-year-old man who presented with 5 years of cutaneous symptoms and several months of fevers and night sweats, ultimately diagnosed as MF. Owing to diffuse CD30 positivity, he was a candidate for brentuximab vedotin, an antibody-drug conjugate medication that selectively targets the CD30 antigen. This resulted in an excellent therapeutic response.

Indexed as

Antineoplastic Agents, ImmunologicalBrentuximab VedotinDermatitis, ExfoliativeDiagnosis, DifferentialHumansKi-1 AntigenMaleMiddle AgedMycosis FungoidesSkin NeoplasmsAntineoplastic Agents, ImmunologicalBrentuximab VedotinKi-1 Antigencancerclinical imagedermatology

Identifiers

PMID31388911
PMCPMC6848709
OpenAlexW2965285700

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.